Specific Aims Examples: Three Annotated Pages

Guidance on the specific aims page is plentiful; specific aims writing samples are not, because most real ones are unpublished. Below are three worked examples in different domains, annotated to show which sentences carry weight and which would lose a reviewer. They are fictional but constructed to the standards reviewers actually apply.

For the underlying structure, see how to write specific aims. This page assumes you know the arc and want to see it executed.

Example 1, NIH R01, chronic disease

Opening. Type 2 diabetes affects 38 million adults in the United States, and roughly 30% of patients on first-line metformin fail to achieve glycemic control within twelve months. Clinicians cannot currently predict which patients will fail, so treatment escalation happens reactively, after months of uncontrolled hyperglycemia. The determinants of early metformin non-response remain poorly characterized, and no validated predictive biomarker exists.

Hypothesis and rationale. Our preliminary data in a retrospective cohort of 412 patients show that a three-gene expression signature in peripheral blood at treatment initiation distinguishes responders from non-responders with an AUC of 0.79. We hypothesize that early metformin non-response is driven by variation in hepatic organic cation transporter expression, and that this variation is detectable in peripheral blood before treatment begins. Our long-term objective is a point-of-care test that guides first-line therapy selection.

Aim 1. Validate the three-gene signature prospectively. We will enroll 600 treatment-naive patients and measure the signature at baseline, with glycemic control at twelve months as the primary endpoint. Expected outcome: a prospectively validated predictive model with a pre-specified AUC target of 0.75.

Aim 2. Determine the mechanism linking transporter expression to non-response. Using primary hepatocytes from 40 donors stratified by signature status, we will measure metformin uptake and downstream AMPK activation. Expected outcome: a mechanistic account of why the signature predicts, which is required for regulatory acceptance of any eventual test.

Aim 3. Establish the assay's performance in a point-of-care format. We will adapt the assay to a dried blood spot platform and compare against the laboratory reference in 200 paired samples. Expected outcome: concordance sufficient to justify a subsequent implementation trial.

Impact. Together these aims deliver a validated, mechanistically grounded, deployable predictor of metformin non-response. Success would allow treatment escalation at initiation rather than after a year of uncontrolled disease, and provides the evidence base for a Phase III implementation trial.

What is working here

The opening leads with the clinical problem and gets to the gap in three sentences. No paragraph about the applicant's laboratory. Reviewers are deciding within about ninety seconds whether this matters; spend that time on why it matters.

The hypothesis is bolded and falsifiable. It could be shown wrong. Contrast the common weak form: "We will investigate the relationship between transporter expression and treatment response." Nothing there can fail.

Preliminary data appear before the hypothesis, briefly, with a number. AUC 0.79 in 412 patients establishes that this is not speculation, in one clause.

The aims are independent. Aim 2 remains valuable if Aim 1's model underperforms, because the mechanistic question stands on its own. Aim 3 is a technical translation that does not require Aim 2. This is the single most common structural failure in submitted aims pages, and it is worth checking explicitly: if Aim 1 returns a null result, is the rest of this project still worth funding?

Every aim states an expected outcome with a pre-specified threshold. "A pre-specified AUC target of 0.75" tells the reviewer you know what success looks like before you start.

Example 2, SBIR Phase I, device

Opening. Hospital-acquired pressure injuries affect 2.5 million U.S. patients annually at an estimated cost of $11 billion. Prevention depends on repositioning immobile patients every two hours, but audits consistently find compliance below 40% on understaffed units. Existing monitoring systems require wearable sensors that are dislodged, uncharged, or refused by patients, and none has achieved sustained adoption.

Innovation and objective. We have developed a pressure-sensing mattress overlay that infers patient position without any device attached to the patient, using a sparse sensor array and a classification model. Bench testing on a 30-subject dataset achieves 91% position-class accuracy. Our Phase I objective is to demonstrate that overlay-derived repositioning data matches clinician observation closely enough to serve as a compliance record in a live ward setting.

Aim 1. Establish accuracy against direct observation in a clinical environment. In two 20-bed units over eight weeks, we will compare overlay-derived position classification against timed observation by trained research staff across 1,200 observation events. Success criterion: ≥85% agreement, weighted kappa ≥0.70.

Aim 2. Determine whether the system is usable by nursing staff without workflow disruption. We will assess setup time, alert response, and false-alarm rate, with a structured usability instrument administered to 25 nurses. Success criterion: median setup under 4 minutes and a false-alarm rate below 1 per bed per shift.

Commercial path. Meeting both criteria de-risks the primary technical and adoption questions and supports a Phase II multi-site trial and a 510(k) submission. Two health systems have provided letters of intent to host Phase II sites.

What is working here

Two aims, not three. Phase I is a feasibility stage with a short period of performance. Three aims in Phase I usually signals that the applicant has not identified the actual risk.

Success criteria are numeric and pre-specified. "≥85% agreement, weighted kappa ≥0.70" is what distinguishes a feasibility study from an exploration. SBIR reviewers look for exactly this, because Phase I exists to answer a yes/no question.

Aim 2 is about adoption, not technology. The stated failure of existing systems was adoption, so the aims test the thing that actually kills the product. Aims that only test what the team enjoys building are a recurring weakness.

The commercial path is concrete. Letters of intent from two health systems, a named regulatory route. Our guide to the SBIR commercialization plan covers how far this needs to go in the full application, and SBIR Phase I vs Phase II covers what each stage is expected to prove.

Example 3, the weak version, for contrast

Here is the same device project written the way it usually arrives:

Pressure injuries are a serious problem in hospitals and have been studied extensively. Our team has significant experience in sensor technology and machine learning, with over 30 publications in the field. We propose to develop an innovative new mattress system to address this important problem.

Aim 1. Develop the sensor array hardware. Aim 2. Train a machine learning model on data collected in Aim 1. Aim 3. Validate the model in a clinical setting using the system from Aims 1 and 2.

This work will have a major impact on patient safety.

Four things have gone wrong, and all four are common:

1. The opening is about the team, not the problem. Reviewers know you are qualified; the biosketch says so. Our NIH biosketch example is where credentials belong.
2. There is no hypothesis and no gap. "Has been studied extensively" actively argues against novelty.
3. The aims are strictly sequential. Aim 2 cannot start until Aim 1 finishes and Aim 3 needs both. A single hardware delay ends the project, and a reviewer will say so.
4. No success criteria and no numbers. "Major impact" is the sentence reviewers stop reading at.

A checklist before you submit the page

• Does sentence one describe a problem, and does the gap appear by sentence four?
• Is there a bolded, falsifiable hypothesis?
• If Aim 1 returns a null result, is the project still worth funding?
• Does every aim have a numeric expected outcome or success criterion?
• Does the final paragraph say what becomes possible next, rather than restating the aims?
• Is it genuinely one page?

To draft against a scaffold, use our specific aims template. For the wider application these pages sit inside, see how to write an SBIR proposal and our overview of NIH grants.